EastWest Bioscience Inc.
EASTH.V
TSX
| 04/30/2022 | 01/31/2022 | 10/31/2021 | 07/31/2021 | 04/30/2021 | |
|---|---|---|---|---|---|
| Revenue | -62.45% | -51.00% | -45.55% | -91.79% | 63.63% |
| Total Other Revenue | 71.92% | 9.13% | -9.58% | 45.31% | 21.69% |
| Total Revenue | -17.85% | -31.67% | -32.53% | -44.06% | 46.85% |
| Cost of Revenue | -53.30% | -52.89% | -45.14% | -47.99% | 48.06% |
| Gross Profit | 1.70% | -9.53% | -22.02% | 158.82% | 46.19% |
| SG&A Expenses | -6.42% | 128.90% | 58.70% | 201.85% | 3.11% |
| Depreciation & Amortization | -18.93% | -10.86% | -10.76% | -13.17% | 28.57% |
| Other Operating Expenses | -- | 143.02% | -26.47% | -1,173.33% | -- |
| Total Operating Expenses | -17.12% | 60.77% | 31.22% | 106.86% | 11.56% |
| Operating Income | 16.04% | -239.84% | -92.60% | -173.56% | 17.68% |
| Income Before Tax | -267.16% | 1,118.22% | -93.12% | -265.70% | 55.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -267.16% | 1,118.22% | -93.12% | -265.70% | 55.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -267.16% | 1,118.22% | -63.86% | -257.14% | 55.74% |
| EBIT | 16.04% | -239.84% | -92.60% | -173.56% | 17.68% |
| EBITDA | 15.55% | -286.39% | -104.74% | -191.22% | 22.39% |
| EPS Basic | -238.46% | 1,070.59% | -60.00% | -225.00% | 59.38% |
| Normalized Basic EPS | -92.86% | -383.33% | -29.41% | -170.83% | 33.33% |
| EPS Diluted | -238.46% | 1,070.59% | -60.00% | -225.00% | 59.38% |
| Normalized Diluted EPS | -92.86% | -383.33% | -29.41% | -170.83% | 33.33% |
| Average Basic Shares Outstanding | 6.26% | 6.47% | 5.13% | 11.23% | 12.47% |
| Average Diluted Shares Outstanding | 6.26% | 6.47% | 5.13% | 11.23% | 12.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
